Is NDA up or down today?
NDA is up 1.48% today, last at 172.88. This stock moved +1.48% versus the prior close.
NDA · NDA
NDA (NDA) is trading at 172.88, up 1.48% on the session. NDA sits at the 50% mark of its 52-week range.
Leading the coverage: “Cullinan Therapeutics (CGEM) Starts Zipalertinib NDA Submission, Is The Stock Still 52% Undervalued? - Simply Wall St” (Google News Company, 29d ago). NDA is -6.80% since story.
NDA trades on a trailing P/E of 39.7.
Analyst firms are mostly reiterating — no strong directional shift lately.
NDA is up 1.48% today, last at 172.88. This stock moved +1.48% versus the prior close.
Leading the coverage: “Cullinan Therapeutics (CGEM) Starts Zipalertinib NDA Submission, Is The Stock Still 52% Undervalued? - Simply Wall St” (Google News Company, 29d ago). NDA is -6.80% since story. Dominant story: Oppenheimer reiterates Compass Pathways stock rating on NDA filing By Investing.com - Investing.com South Africa (1 source, neutral) RSI unavailable Price sits at 50% of its 52-week range Social sentiment loads separately — see the Social tab.
Analyst firms are mostly reiterating — no strong directional shift lately.
Historical price chart unavailable
Live quote in the header is real, but OHLC history could not be loaded from Yahoo Finance or fallback providers. Charts use Yahoo when configured correctly — check server logs for provider errors.
Oppenheimer reiterates Compass Pathways stock rating on NDA filing By Investing.com - Investing.com South Africa
Compass Pathways stock maintained at Buy by TD Cowen ahead of NDA filing - Investing.com
What Could Neptune Digital Assets’ (TSXV:NDA) SpaceX Investment and Options Strategy Mean for Its Portfolio? - Kalkine Media
Stifel reiterates Compass Pathways stock rating on NDA progress - Investing.com
CMPS: Phase 3 TRD success supports a Q4 2026 NDA and conditional H1 2027 launch - TradingView